USC-UCLA Drug-Induced Liver Injjry (DILI) Clinical Center

USC-UCLA 药物性肝损伤 (DILI) 临床中心

• 批准号: 8330957
• 负责人: ANDREW Abba STOLZ
• 金额: $ 25.86万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-30 至 2013-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8330957
• 关键词: Ancillary Study; Awareness; Clinical; Clinical Data; Collection; Consent Forms; County; Coupled; Enrollment; Future; Goals; Health Personnel; Healthcare Systems; Injury; Institutional Review Boards; Joints; Knowledge; Liver; Los Angeles; Manuals; Medical center; Pharmaceutical Preparations; Pharmacists; Population Heterogeneity; Preparation; Principal Investigator; Process; Protocols documentation; Public Health; Publications; Published Comment; Research Infrastructure; Research Personnel; Resources; Scientific Advances and Accomplishments; Shipping; Ships; Site; Site Visit; Source; Specimen; System; Talents; Testing; United States; base; design; interest; medical schools; meetings; operation; patient population; population based; repository; research clinical testing; response; tool

DESCRIPTION (provided by applicant): The USC-UCLA Drug Induced Liver Injury (DILI) Clinical Center (CC) proposal in response to RFA-DK-07-012 "Continuation and Expansion of the Drug Induced Liver Injury Network (DILIN)" hopes to joint the other established CCs to advance the scientific knowledge and the clinical evaluation of DILI. Our proposal combines the only two medical schools in Los Angeles County allowing us to uniquely capture DILI cases in this large, ethnically diverse population. The 10.3 M residents of Los Angeles County (2007) are an unmatched resource composed of the most ethnically diverse populations in the United States. We have proposed to increase the identification of potential DILI cases within the health care systems of USC, UCLA and the County of Los Angeles Department of Public Health by developing didactic tools targetted to specific groups of health care providers. In addition to our unique patient population, this proposal is built upon the expertise and talents from the USC and UCLA Medical Centers. The Specific Aims of the USC-UCLA DILI CC are to: 1) Review existing DILIN documents in preparation for joining the DILIN 2) Establish the USC-UCLA DILI CC infrastructure at USC and UCLA, 3) Establish the toll-free referral line and distribute IRB-approved documents to networks of potential health care providers and pharmacists who will be a referral sources for potential DILI cases. 4) Develop educational tools to increase DILI awareness and to enhance DILI case referrals from both affiliated and non-affiliated health care providers 5) Screen and enroll eligible subjects into the DILIN for collection of clinical data and specimens 6) Collaborate with other investigators, participate in the organization and operation of the DILIN, and assist with the design of future ancillary studies.

描述（由申请人提供）： USC-UCLA药物诱导肝损伤（DILI）临床中心（CC）提案 RFA-DK-07-012“药物诱导的肝损伤网络（DILIN）的延续和扩展”希望与其他已建立的CC结合，以推进DILI的科学知识和临床评估。我们的提议结合了洛杉矶县仅有的两所医学院，使我们能够在这个大型的种族多样化的人口中唯一捕获DILI案件。洛杉矶县（2007年）的10.3 m居民是一种无与伦比的资源，由美国最多样化的人口组成。我们建议通过开发针对特定的卫生保健提供者组的教学工具来增加UCLA卫生保健系统和洛杉矶县公共卫生县医疗保健系统中潜在DILI案件的识别。除了我们独特的患者人数外，该提案还基于加州大学和加州大学洛杉矶分校医疗中心的专业知识和才能。 USC-UCLA DILI CC的具体目的是：1）审查现有的稀释文档以准备加入DILIN 2）在USC和UCLA上建立USC-UCLA DILI CC基础设施将IRB批准的文档分发给潜在的医疗保健提供者和药剂师网络，这些文件将成为潜在的DILI病例的转诊来源。 4）开发教育工具，以提高稀释意识并增强附属和非附属医疗保健提供者的DILI案例转介5）筛选并将符合条件的受试者注册到稀释层中，以收集临床数据和标本6）与其他调查人员合作，参与在Dilin的组织和运营中，并协助设计未来的辅助研究。